Previous Close | 52.88 |
Open | 52.86 |
Bid | 54.61 x 200 |
Ask | 55.12 x 100 |
Day's Range | 51.80 - 56.42 |
52 Week Range | 12.45 - 67.21 |
Volume | |
Avg. Volume | 203,295 |
Market Cap | 936.417M |
Beta (5Y Monthly) | 2.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -18.69 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 138.60 |
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showca
Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April. Praxis management will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference, taking place vi